Merus N.V. Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Merus N.V.'s estimated annual revenue is currently $42.6M per year.(i)
  • Merus N.V.'s estimated revenue per employee is $155,000

Employee Data

  • Merus N.V. has 275 Employees.(i)
  • Merus N.V. grew their employee count by 24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Our most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways. Working at Merus offers opportunity to grow and develop a career that offers both individual and company success. You have the chance to make an impact within the oncology field by being part of the development of bispecific antibody therapies (Biclonics®) to help fight cancer. Merus’ Head Quarters are located in The Netherlands, with offices in the US and collaborators around the world. As of 2016 we are listed on NASDAQ and over a period of 10 years we have several candidate drugs in clinical trials. For more information, please visit www.merus.nl

keywords:N/A

N/A

Total Funding

275

Number of Employees

$42.6M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Merus N.V. News

2022-04-06 - Merus Presents Preclinical Data on MCLA-129 at the ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”,...

2022-04-06 - Should You Buy Merus NV (MRUS) in Biotechnology Industry?

MRUS received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Merus NV also achieved a score of 87 in...

2022-03-30 - Rallybio Appoints Christine A. Nash and Hui Liu, Ph.D., to Its ...

He is currently the Executive Vice President, Chief Business Officer and Head of US at Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology...

2021-11-02 - Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Quarter and Provides Business Update

Merus participated in a Type B meeting with the FDA regarding its zenocutuzumab development program and obtained alignment with FDA on registration approach for a potential tumor agnostic indicationMerus presented early clinical data on MCLA-158 at the AACR-NCI-EORTC Virtual International Confer ...

2021-09-30 - Merus N : Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the pu ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$79.8M275-1%$3M
#2
$62.8M27847%$240.8M
#3
$49.1M2791%N/A
#4
$83.2M28047%N/A
#5
$31.5M2816%N/A